1. Cancer Therapeutics
2. Health Disparities
3. Small molecules
4. Transcription factors
5. Cancer drug resistance

Dr. Basha's research is in the area of experimental therapeutics. The aberrant expression of certain molecular markers is associated with aggressive disease and poor prognosis in a variety of human malignancies. His lab is working on targeting c-Met (a receptor for hepatocyte growth factor), Specificity protein 1 (Sp1) transcription factor and survivin or baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5), an inhibitor of anti-apoptotic protein for enhancing therapeutic efficacy in cancer. These markers are associated with resistance to chemo- and radiation therapies and impact the disease progression and prognosis of cancer patients. We are testing certain investigational agents that have the ability to target these candidates focusing on developing strategies to improve therapeutic efficacy in breast cancer, Ewing sarcoma, Hepatocellular carcinoma, ovarian and pancreatic cancers using preclinical models and clinical specimens. We are also evaluating the combination of investigational agents and standard chemotherapeutic agents to enhance the therapeutic efficacy and reducing morbidity. In addition, cancer health disparities, collaborating with Artificial Intelligence/Machine Learning (AI/ML) experts, oncologists, geneticists and molecular pathologists on genetic testing and pharmacogenomics to precisely understand individualized response to therapies.  Dr. Basha’s research projects designed to exploit the genomic biomarkers, genomic profiling/sequencing, and liquid biopsy for identifying precise therapeutic options. Dr. Basha is actively working with the collaborators (physicians and translational researchers) in DFW area including Cook Children’s and JPS and other institutions including NCI-designated comprehensive cancer centers for developing less toxic and effective strategies for treating human cancers.

1. Molecular biology
2. Proteomics
3. NGS